Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-PARK7/DJ1 Antibody (9Q473) is a Rabbit antibody targeting PARK7/DJ1. Anti-PARK7/DJ1 Antibody (9Q473) can be used in FCM,ICC/IF,IHC,IP,WB.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
50 μL | $296 | 7-10 days | |
100 μL | $496 | 7-10 days |
Description | Anti-PARK7/DJ1 Antibody (9Q473) is a Rabbit antibody targeting PARK7/DJ1. Anti-PARK7/DJ1 Antibody (9Q473) can be used in FCM,ICC/IF,IHC,IP,WB. |
Synonyms | parkinson protein 7, HEL-S-67p, DJ-1, DJ1 |
Ig Type | IgG |
Clone | 9Q473 |
Reactivity | Human,Mouse,Rat |
Verified Activity | 1. Western blot analysis of PARK7 on different lysates using anti-PARK7 antibody at 1/1,000 dilution. Positive control: Lane 1: Hela, Lane 2: Jurkat, Lane 3: NIH/3T3. 2. Immunohistochemical analysis of paraffin-embedded human breast tissue using anti-PARK7 antibody. Counter stained with hematoxylin. 3. Immunohistochemical analysis of paraffin-embedded human kidney tissue using anti-PARK7 antibody. Counter stained with hematoxylin. 4. Immunohistochemical analysis of paraffin-embedded human pancreas tissue using anti-PARK7 antibody. Counter stained with hematoxylin. 5. Immunohistochemical analysis of paraffin-embedded mouse prostate tissue using anti-PARK7 antibody. Counter stained with hematoxylin. 6. Immunohistochemical analysis of paraffin-embedded mouse pancreas tissue using anti-PARK7 antibody. Counter stained with hematoxylin. 7. ICC staining PARK7 in HepG2 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS. 8. ICC staining PARK7 in MCF-7 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS. 9. Flow cytometric analysis of HepG2 cells with PARK7 antibody at 1/50 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black). Alexa Fluor 488-conjugated goat anti rabbit IgG was used as the secondary antibody. |
Application | |
Recommended Dose | WB: 1:1000-2000; IHC: 1:100-500; ICC/IF: 1:100-500; FCM: 1:50-100 |
Antibody Type | Monoclonal |
Host Species | Rabbit |
Construction | Recombinant Antibody |
Purification | ProA affinity purified |
Appearance | Liquid |
Formulation | 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide. |
Research Background | PARK7/DJ1 is a ubiquitously expressed protein involved in various cellular processes including cell proliferation, RNA-binding, and oxidative stress. The protein has been found to colocalize within a subset of pathologic tau inclusions in a diverse group of neurodegenerative disorders known as tauopathies. Defects in PARK7/DJ1 are the cause of autosomal recessive early-onset Parkinson's disease 7 (PARK7). Parkinson's disease (PD) is a complex, multifactorial disorder that typically manifests after the age of 50 years. The disease is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. PARK7 is characterized by onset before 40 years and slow progression. It has also been suggested that PARK7/DJ1 is a mitogen dependent oncogene product involved in Ras related signal transduction pathways. |
Conjucates | Unconjugated |
Immunogen | Recombinant Protein |
Uniprot ID |
Molecular Weight | Theoretical: 20 kDa. |
Stability & Storage | Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.